Defining EGFR amplification status for clinical trial inclusion
Pim J. French(Erasmus MC Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute), Michael Weller(University Hospital of Zurich), Iris de Heer(Erasmus MC Cancer Institute), Jim Looman(AbbVie (United States)), Earle Bain(AbbVie (United States)), Peter Ansell(AbbVie (United States)), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Jean‐Sébastien Frenel(Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers), Marica Eoli(Fondazione IRCCS Istituto Neurologico Carlo Besta), Enrico Franceschi(Istituto delle Scienze Neurologiche di Bologna), Marie Morfouace(European Organisation for Research and Treatment of Cancer), Johan M. Kros(Erasmus MC), Paul M. Clément(Universitair Ziekenhuis Leuven), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Annemiek Walenkamp(University Medical Center Groningen)
Cited by 44
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k